Novel Strategy for Three-Dimensional Fragment-Based Lead Discovery

被引:17
|
作者
Yuan, Haoliang [1 ]
Lu, Tao [1 ]
Ran, Ting [1 ]
Liu, Haichun [1 ]
Lu, Shuai [1 ]
Tai, Wenting [1 ]
Leng, Ying [1 ]
Zhang, Weiwei [1 ]
Wang, Jian [1 ]
Chen, Yadong [1 ]
机构
[1] China Pharmaceut Univ, Lab Mol Design & Drug Discovery, Sch Basic Sci, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
DEPENDENT KINASE INHIBITORS; STRUCTURE-GUIDED DESIGN; HIGH-AFFINITY LIGANDS; C-MET INHIBITORS; DRUG DESIGN; CDK2; INHIBITORS; ANILINO PYRIMIDINES; SELECTIVE CLASS; BINDING MODE; POTENT;
D O I
10.1021/ci200003c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based drug design (FBDD) is considered a promising approach in lead discovery. However, for a practical application of this approach, problems remain to be solved. Hence, a novel practical strategy for three-dimensional lead discovery is presented in this work Diverse fragments with spatial positions and orientations retained in separately adjacent regions were generated by deconstructing well-aligned known inhibitors in the same target active site. These three-dimensional fragments retained their original binding modes in the process of new molecule construction by fragment linking and merging. Root-mean-square deviation (rmsd) values were used to evaluate the conformational changes of the component fragments in the final compounds and to identify the potential leads as the main criteria. Furthermore, the successful validation of our strategy is presented on the basis of two relevant tumor targets (CDK2 and c-Met), demonstrating the potential of our strategy to facilitate lead discovery against some drug targets.
引用
收藏
页码:959 / 974
页数:16
相关论文
共 50 条
  • [41] Electron Density Guided Fragment-Based Lead Discovery of Ketohexokinase Inhibitors
    Gibbs, Alan C.
    Abad, Marta C.
    Zhang, Xuqing
    Tounge, Brett A.
    Lewandowski, Francis A.
    Struble, Geoffrey T.
    Sun, Weimei
    Sui, Zhihua
    Kuo, Lawrence C.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (22) : 7979 - 7991
  • [42] Fragment-based lead discovery on G-protein-coupled receptors
    Visegrady, Andras
    Keseru, Gyorgy M.
    EXPERT OPINION ON DRUG DISCOVERY, 2013, 8 (07) : 811 - 820
  • [43] An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery
    Linke, Pawel
    Amaning, Kwame
    Maschberger, Melanie
    Vallee, Francois
    Steier, Valerie
    Baaske, Philipp
    Duhr, Stefan
    Breitsprecher, Dennis
    Rak, Alexey
    JOURNAL OF BIOMOLECULAR SCREENING, 2016, 21 (04) : 414 - 421
  • [44] Fragment-based Discovery of Potential Anticancer Lead: Computational and in vitro Studies
    Balgoname, Abdulmalek A.
    Alomair, Sufyan M.
    AlMubirek, Abdulrahman K.
    Khedr, Mohammed A.
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2021, 17 (03) : 421 - 428
  • [45] Fragment-based lead discovery using X-ray crystallography
    Hartshorn, MJ
    Murray, CW
    Cleasby, A
    Frederickson, M
    Tickle, IJ
    Jhoti, H
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (02) : 403 - 413
  • [46] Process of Fragment-Based Lead Discovery-A Perspective from NMR
    Ma, Rongsheng
    Wang, Pengchao
    Wu, Jihui
    Ruan, Ke
    MOLECULES, 2016, 21 (07):
  • [47] Fragment-Based Discovery of Novel MUS81 Inhibitors
    Collie, Gavin W.
    Borjesson, Ulf
    Chen, Yunhua
    Dong, Zhiqiang
    Di Fruscia, Paolo
    Gohlke, Andrea
    Hoyle, Anna
    Hunt, Thomas A.
    Jesani, Mehul H.
    Luo, Haiou
    Luptak, Jakub
    Milbradt, Alexander G.
    Narasimhan, Priyanka
    Packer, Martin
    Patel, Saleha
    Qiao, Jingchuan
    Storer, R. Ian
    Stubbs, Christopher J.
    Tart, Jonathan
    Truman, Caroline
    Wang, Anderson T.
    Wheeler, Matthew G.
    Winter-Holt, Jon
    ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (07): : 1151 - 1158
  • [48] Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors
    Alen, Jo
    Schade, Markus
    Wagener, Markus
    Christian, Frank
    Nordhoff, Sonja
    Merla, Beatrix
    Dunkern, Torsten R.
    Bahrenberg, Gregor
    Ratcliffe, Paul
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (13) : 6391 - 6397
  • [49] Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets
    Li, Qingxin
    Kang, Congbao
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2021, 21 (13) : 1099 - 1112
  • [50] Integrating novel biophysical approaches in fragment-based lead discovery workflow: MST and nDSF for screening and validation
    Rak, A.
    JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2018, 50 (06) : 503 - 503